Free tool
FAERS Monitor: Myxredlin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 208157 or its brand name (Myxredlin, Insulin Human). Reports on generic versions are filed under their own applications.
Reports
6,745
Serious
5,542
82% of reports
Hospitalization
3,116
Death reported
779
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased966
- hypoglycaemia434
- drug ineffective380
- dyspnoea331
- hyperglycaemia329
- diarrhoea325
- blood glucose decreased295
- off label use291
- headache257
- nausea250
- fall246
- weight decreased242
- vomiting237
- wrong technique in product usage process236
- fatigue230
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 54 |
| 2006 | 44 |
| 2007 | 73 |
| 2008 | 69 |
| 2009 | 67 |
| 2010 | 76 |
| 2011 | 100 |
| 2012 | 96 |
| 2013 | 160 |
| 2014 | 369 |
| 2015 | 909 |
| 2016 | 196 |
| 2017 | 143 |
| 2018 | 385 |
| 2019 | 349 |
| 2020 | 310 |
| 2021 | 410 |
| 2022 | 665 |
| 2023 | 607 |
| 2024 | 651 |
| 2025 | 585 |
| 2026 | 373 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,414 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 329 | 28.4 | 25.5 | 8,607 |
| hypoglycaemiaSignal | 434 | 28.1 | 25.7 | 11,260 |
| blood glucose decreasedSignal | 295 | 19.3 | 17.2 | 5,072 |
| blood glucose increasedSignal | 966 | 16.1 | 15.2 | 13,685 |
| wrong technique in product usage processSignal | 236 | 3.6 | 3.2 | 452 |
| weight decreasedSignal | 242 | 2.7 | 2.4 | 262 |
| fallSignal | 246 | 2.3 | 2.0 | 183 |
| dyspnoea | 331 | 1.8 | 1.6 | 126 |
| vomiting | 237 | 1.6 | 1.4 | 50 |
| diarrhoea | 325 | 1.6 | 1.4 | 69 |
| headache | 257 | 1.3 | 1.1 | 16 |
| off label use | 291 | 1.0 | 0.9 | 0 |
| nausea | 250 | 1.0 | 0.9 | 0 |
| fatigue | 230 | 0.9 | 0.8 | 2 |
| drug ineffective | 380 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.